Advanced search
7 files | 3.90 MB Add to list

Aligning Quality of Life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour

Author
Organization
Abstract
Introduction Adults with intellectual disabilities have an increased vulnerability to mental health problems and challenging behaviour. In addition to psychotherapeutic or psychoeducational methods, off-label pharmacotherapy, is a commonly used treatment modality. Objective The aim of this study was to establish evidence-based guideline recommendations for the responsible prescription of off-label psychotropic drugs, in relation to Quality of Life (QoL). Method A list of guidelines was selected, and principles were established based on international literature, guideline review and expert evaluation. The Delphi method was used to achieve consensus about guideline recommendations among a 58-member international multidisciplinary expert Delphi panel. Thirty-three statements were rated on a 5-point Likert-scale, ranging from totally disagree to totally agree, in consecutive Delphi rounds. When at least 70% of the participants agreed (score equal or higher than 4), a statement was accepted . Statements without a consensus were adjusted between consecutive Delphi rounds based on feedback from the Delphi panel. Results Consensus was reached on 4 general:the importance of non-pharmaceutical treatments, comprehensive diagnostics and multidisciplinary treatment. Consensus was reached in 4 rounds on 29 statements. No consensus was reached on 4 statements concerning: freedom-restricting measures, the treatment plan, the evaluation of the treatment plan, and the informed consent. Conclusion The study led to recommendations and principles for the responsible prescription - aligned with the QoL perspective - of off-label psychotropic drugs for adults with intellectual disabilities and challenging behaviour. Extensive discussion is needed regarding the issues on which there was no consensus to furthering the ongoing development of this guideline.
Keywords
Delphi study, challenging behaviour, guidelines, off-label use, intellectual disability, psychotropic drugs, quality of life

Downloads

  • (...).pdf
    • supplementary material
    • |
    • UGent only
    • |
    • PDF
    • |
    • 479.68 KB
  • (...).pdf
    • supplementary material
    • |
    • UGent only
    • |
    • PDF
    • |
    • 524.77 KB
  • (...).pdf
    • supplementary material
    • |
    • UGent only
    • |
    • PDF
    • |
    • 341.80 KB
  • (...).pdf
    • supplementary material
    • |
    • UGent only
    • |
    • PDF
    • |
    • 373.05 KB
  • (...).pdf
    • supplementary material
    • |
    • UGent only
    • |
    • PDF
    • |
    • 607.94 KB
  • (...).pdf
    • supplementary material
    • |
    • UGent only
    • |
    • PDF
    • |
    • 193.06 KB
  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.38 MB

Citation

Please use this url to cite or link to this publication:

MLA
Laermans, Pauline, et al. “Aligning Quality of Life and Guidelines for Off-Label Psychotropic Drugs in Adults with Intellectual Disabilities and Challenging Behaviour.” INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES, vol. 69, no. 3, 2023, pp. 398–413, doi:10.1080/20473869.2023.2195721.
APA
Laermans, P., Morisse, F., Lombardi, M., Gérard, S., Vandevelde, S., de Kuijper, G., … Claes, C. (2023). Aligning Quality of Life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour. INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES, 69(3), 398–413. https://doi.org/10.1080/20473869.2023.2195721
Chicago author-date
Laermans, Pauline, Filip Morisse, Marco Lombardi, Sylvie Gérard, Stijn Vandevelde, Gerda de Kuijper, Kurt Audenaert, and Claudia Claes. 2023. “Aligning Quality of Life and Guidelines for Off-Label Psychotropic Drugs in Adults with Intellectual Disabilities and Challenging Behaviour.” INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES 69 (3): 398–413. https://doi.org/10.1080/20473869.2023.2195721.
Chicago author-date (all authors)
Laermans, Pauline, Filip Morisse, Marco Lombardi, Sylvie Gérard, Stijn Vandevelde, Gerda de Kuijper, Kurt Audenaert, and Claudia Claes. 2023. “Aligning Quality of Life and Guidelines for Off-Label Psychotropic Drugs in Adults with Intellectual Disabilities and Challenging Behaviour.” INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES 69 (3): 398–413. doi:10.1080/20473869.2023.2195721.
Vancouver
1.
Laermans P, Morisse F, Lombardi M, Gérard S, Vandevelde S, de Kuijper G, et al. Aligning Quality of Life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour. INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES. 2023;69(3):398–413.
IEEE
[1]
P. Laermans et al., “Aligning Quality of Life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour,” INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES, vol. 69, no. 3, pp. 398–413, 2023.
@article{01GWP4QJD242VW1JVP9K1Y4J9G,
  abstract     = {{Introduction Adults with intellectual disabilities have an increased vulnerability to mental health problems and challenging behaviour. In addition to psychotherapeutic or psychoeducational methods, off-label pharmacotherapy, is a commonly used treatment modality. Objective The aim of this study was to establish evidence-based guideline recommendations for the responsible prescription of off-label psychotropic drugs, in relation to Quality of Life (QoL). Method A list of guidelines was selected, and principles were established based on international literature, guideline review and expert evaluation. The Delphi method was used to achieve consensus about guideline recommendations among a 58-member international multidisciplinary expert Delphi panel. Thirty-three statements were rated on a 5-point Likert-scale, ranging from totally disagree to totally agree, in consecutive Delphi rounds. When at least 70% of the participants agreed (score equal or higher than 4), a statement was accepted . Statements without a consensus were adjusted between consecutive Delphi rounds based on feedback from the Delphi panel. Results Consensus was reached on 4 general:the importance of non-pharmaceutical treatments, comprehensive diagnostics and multidisciplinary treatment. Consensus was reached in 4 rounds on 29 statements. No consensus was reached on 4 statements concerning: freedom-restricting measures, the treatment plan, the evaluation of the treatment plan, and the informed consent. Conclusion The study led to recommendations and principles for the responsible prescription - aligned with the QoL perspective - of off-label psychotropic drugs for adults with intellectual disabilities and challenging behaviour. Extensive discussion is needed regarding the issues on which there was no consensus to furthering the ongoing development of this guideline.}},
  author       = {{Laermans, Pauline and Morisse, Filip and Lombardi, Marco and Gérard, Sylvie and Vandevelde, Stijn and de Kuijper, Gerda and Audenaert, Kurt and Claes, Claudia}},
  issn         = {{2047-3869}},
  journal      = {{INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES}},
  keywords     = {{Delphi study,challenging behaviour,guidelines,off-label use,intellectual disability,psychotropic drugs,quality of life}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{398--413}},
  title        = {{Aligning Quality of Life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour}},
  url          = {{http://doi.org/10.1080/20473869.2023.2195721}},
  volume       = {{69}},
  year         = {{2023}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: